Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. CytRx
CYTR

Buy CytRx (CYTR) Stock

CYTR
See CYTR stock price and Buy/Sell CytRx with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
CYTR

CytRx (CYTR)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About CytRx (CYTR)

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highl...Read more
Market Cap
$5.58M
1 Year High
$4.70
Volume
1 Year Low
$0.09
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch CYTR stock

CytRx Stock News

CytRx stock rating

What analysts recommend for CYTR stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1

CytRx price target

What analysts think CYTR will be worth
Low $0
High $4.70
Current $0
Target $4

Events

List of events that could affect CYTR stock.
12May

Earnings data Q1 2022

11Aug

Earnings data Q2 2022

CytRx earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.03
-0.06
-0.09
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019

Expected EPS
Q4 2019
-$0.05
Actual EPS
Q4 2019
-$0.09

Buy CytRx (CYTR) Stock

CYTR
See CYTR stock price and Buy/Sell CytRx with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch CYTR stock
  • aevin26 avatar
  • pamaguin avatar
  • Bhuiyansuman13 avatar
  • daniellev93 avatar
  • Dkowski45 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.